DrugDeal Decode

Exploring the Latest MSLN ADC Deal by Harbour Biomed Therapeutics: A Guide to Rapidly Accessing Transaction Insights

15 January 2024
4 min read

Harbour Biomed Therapeutics Ltd. and its wholly-owned subsidiary, Nona Biosciences, recently announced that they have signed an exclusive licensing agreement with Pfizer Inc. for the global clinical development and commercialization of the anti-mesothelin (MSLN) antibody-drug conjugate (ADC) HBM9033. According to the terms of the agreement, Harbour BioMed will receive an upfront and near-term payment of $53 million, as well as up to $1.05 billion in potential milestone payments. In addition, Harbour BioMed is also eligible to receive tiered royalties on net sales that range from high single-digit to high teens percentages.

About HBM9033

HBM9033 is an antibody drug conjugate (ADC) and monoclonal antibody that is being developed for the treatment of neoplasms, specifically solid tumors. HBM9033 is being developed by two organizations, Harbour BioMed (Shanghai) Co., Ltd. and Suzhou Medilink Therapeutics Ltd. Currently, HBM9033 is in the highest phase of clinical development, which is Phase 1. The specific therapeutic areas that HBM9033 is targeting are neoplasms, which refer to abnormal growths of tissue that can be cancerous. Click the image below to directly embark on the exploration journey with the HBM9033!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

HBM9033 specifically targets MSLN, a tumor-associated antigen that is upregulated in a variety of solid tumors, including mesothelioma, ovarian cancer, lung cancer, breast cancer, and pancreatic cancer. This ADC utilizes a tumor-specific cleavable linker and a novel topoisomerase inhibitor payload to enhance stability and potency. Its unique antibody and linker-payload design have demonstrated outstanding efficacy and safety in preclinical studies.

About Harbour Biomed Therapeutics Ltd.

Harbour Biomed Therapeutics Ltd. is a relatively young company that has made significant progress in the development of drugs in various therapeutic areas. The company's focus on Neoplasms and Immune System Diseases reflects the growing demand for innovative treatments in these areas. The diverse range of molecular targets being pursued by the company indicates a commitment to exploring novel approaches for drug development. With a substantial number of drugs in the preclinical stage and several in advanced clinical stages, Harbour Biomed Therapeutics Ltd. has a promising pipeline that could potentially lead to the development of new therapies for patients in need.

图形用户界面, 应用程序

描述已自动生成

By engaging in proprietary research and diversified collaboration, Harbour BioMed has rapidly expanded its new drug research and development pipeline, which now boasts a robust lineup including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs). From the perspective of immune pathways, the pipeline covers direct-killing agents, T cell recruiters, T/NK cell activators, NK cell recruiters, and therapies that relieve immunosuppression in the tumor microenvironment, among others.

How to get the latest progress on drug deals?

If you would like to access the latest transaction event information, you can click on the 'Deal' module from the homepage of the Synapse database. Within the Deal module, you can search for global pharmaceutical transaction information using labels such as Drugs, Organization, Target, Drug Type, Deal Date. 

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Furthermore, you can obtain the original link to the transaction coverage by clicking on the "Deal Name."

图形用户界面, 应用程序

描述已自动生成

In the analysis view, you can see the most active assignors, assignees, popular targets, and other dimensions of analysis, as well as the distribution of research and development statuses at the time of the transaction, to help you better understand the search results.

图表

描述已自动生成

The Synapse database also supports the ability to view current transactions from the dimension of "drugs" (by selecting "drugs" from the "Adjust Dimension" dropdown menu above). Targeting transactions involving renowned pharmaceutical companies that are of interest to the industry, such as Merck, Roche, etc., Synapse has identified a group of "leading companies" through drugs that have achieved global sales exceeding 1 billion US dollars in 2022. Transactions involving drugs from these leading companies can be filtered by clicking on the "Leading Company" tag on the left-hand side.

图形用户界面, 应用程序, Teams

描述已自动生成

In addition to the drug transaction module, you can also view related transaction history on the drug detail page and the institution detail page.

图形用户界面, 文本, 应用程序

描述已自动生成

Click on the image below to embark on a brand new journey of drug discovery!

Lutikizumab Shows Promise in Phase 2 Trial for Moderate to Severe Hidradenitis Suppurativa, Advances to Next Study Phase
Latest Hotspot
3 min read
Lutikizumab Shows Promise in Phase 2 Trial for Moderate to Severe Hidradenitis Suppurativa, Advances to Next Study Phase
15 January 2024
Lutikizumab Demonstrates Encouraging Outcomes in Phase 2 Study Among Individuals with Moderate to Advanced Hidradenitis Suppurativa, Progressing to Next Trial Stage.
Read →
What is the importance of clinical trial data management system?
"What" Series
2 min read
What is the importance of clinical trial data management system?
15 January 2024
The data management process involves system setup, CRF/database creation, data collection/entry, validation/querying, medical coding, handling external data, blind reviews, database locking, data export/exchange, and archiving documentation.
Read →
Exploring the Latest KRAS G12C Inhibitor Deal by Innovent Biologics: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest KRAS G12C Inhibitor Deal by Innovent Biologics: A Guide to Rapidly Accessing Transaction Insights
13 January 2024
The CDE recently accepted Innovent Biologics and GenFleet Therapeutics' joint NDA for GF-105, prioritizing its review for advanced NSCLC patients with the KRAS G12C mutation after first-line therapy.
Read →
Igrelimogene litadenorepvec: A Quick Look at Its R&D Progress and Clinical Results from the 2023 ESMO_IO
ESMO 2023
4 min read
Igrelimogene litadenorepvec: A Quick Look at Its R&D Progress and Clinical Results from the 2023 ESMO_IO
13 January 2024
The latest clinical findings of Igrelimogene litadenorepvec were unveiled at the 2023 ESMO_IO, demonstrating its potential benefit and setting the stage for subsequent investigations.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.